Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

Phase 2

Completed

Conditions: Non-Neoplastic Hematologic and Lymphocytic Disorder

Interventions: Biological: Anti-Thymocyte Globulin
Procedure: Allogeneic Bone Marrow Transplantation
Drug: Cyclosporine
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Methotrexate
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Radiation: Total-Body Irradiation
Drug: Tacrolimus
Procedure: Umbilical Cord Blood Transplantation
Drug: Treosulfan

First Posted Date: 2009-06-12

Last Posted Date: 2021-08-13

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 98

Registration Number: NCT00919503

Locations: 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

and more 3 locations

Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia
Stage II Chronic Lymphocytic Leukemia
Stage I Chronic Lymphocytic Leukemia
Stage I Small Lymphocytic Lymphoma
Stage III Small Lymphocytic Lymphoma
Stage IV Small Lymphocytic Lymphoma
Stage II Small Lymphocytic Lymphoma
Stage III Chronic Lymphocytic Leukemia
Stage IV Chronic Lymphocytic Leukemia

Interventions: Drug: Fludarabine Phosphate
Drug: Cyclophosphamide
Biological: Rituximab
Drug: Vorinostat

First Posted Date: 2009-06-11

Last Posted Date: 2020-02-25

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 40

Registration Number: NCT00918723

Locations: 🇺🇸
Swedish Cancer Institute-Breast Center at First Hill Campus, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin

Phase 2

Terminated

Conditions: Myelodysplastic Syndromes
Leukemia, Myeloid, Acute

Interventions: Drug: Fludarabine
Drug: Busulphan
Drug: Thymoglobuline (Anti-thymocyte globulin [rabbit]) - Genzyme
Procedure: Haematopoietic stem cell infusion

First Posted Date: 2009-06-08

Last Posted Date: 2011-08-17

Lead Sponsor: King's College Hospital NHS Trust

Target Recruit Count: 20

Registration Number: NCT00915811

Locations: 🇬🇧
King's College Hospital NHS Foundation Trust, London, United Kingdom

Pilot Study of Unrelated Cord Blood Transplantation

Phase 2

Terminated

Conditions: Leukemia, Myeloid, Acute
Leukemia, Lymphoblastic, Acute
Lymphoma, Non-Hodgkin
Chronic Lymphocytic Leukemia
Myelodysplastic Syndromes
Hodgkin Disease

Interventions: Drug: Thiotepa
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Melphalan
Radiation: Radiotherapy
Drug: Intravenous busulphan
Drug: Thymoglobulin
Drug: Ciclosporin
Drug: Mycophenolate mofetil (MMF)

First Posted Date: 2009-06-08

Last Posted Date: 2015-02-11

Lead Sponsor: King's College Hospital NHS Trust

Target Recruit Count: 40

Registration Number: NCT00916045

Locations: 🇬🇧
King's College Hosptial NHS Foundation Trust, London, United Kingdom

Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

Phase 2

Terminated

Conditions: Leukemia
Graft Versus Host Disease
Myelodysplastic Syndromes

Interventions: Drug: Fludarabine Phosphate
Drug: Tacrolimus
Drug: Thiotepa
Radiation: Total-Body Irradiation (TBI)
Other: Magnetic Affinity Cell Sorting
Procedure: Peripheral Blood Stem Cell Transplantation
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Biological: T Cell-Depleted Hematopoietic Stem Cell Transplantation

First Posted Date: 2009-06-05

Last Posted Date: 2020-08-20

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 41

Registration Number: NCT00914940

Locations: 🇺🇸
Yale University School of Medicine/Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma

Phase 2

Conditions: Lymphoma

First Posted Date: 2009-05-22

Last Posted Date: 2013-08-02

Lead Sponsor: Cancer Research UK

Target Recruit Count: 49

Registration Number: NCT00907036

Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma

Phase 1

Active, not recruiting

Conditions: Sarcoma

Interventions: Genetic: Autologous HER2-specific T cells
Drug: Fludarabine
Drug: Cyclophosphamide
Genetic: Autologous CAR Positive T cells

First Posted Date: 2009-05-14

Last Posted Date: 2024-12-27

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 36

Registration Number: NCT00902044

Locations: 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

Phase 2

Terminated

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Lenalidomide
Drug: Fludarabine
Drug: Rituximab
Procedure: Stem Cell Transplantation
Drug: Thymoglobulin
Drug: Bendamustine
Drug: Allopurinol

First Posted Date: 2009-05-12

Last Posted Date: 2020-01-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 39

Registration Number: NCT00899431

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.

Phase 1

Completed

Conditions: Hematologic Malignancies
Allogeneic Stem Cell Transplantation

Interventions: Drug: Fludarabine
Drug: Melphalan
Drug: Antithymocyte Globulin
Drug: Sirolimus
Drug: Tacrolimus

First Posted Date: 2009-04-29

Last Posted Date: 2013-10-08

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 12

Registration Number: NCT00890500

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Early Phase 1

Terminated

Conditions: Epidermolysis Bullosa

Interventions: Drug: Palifermin
Drug: Fludarabine
Drug: Busulfan
Drug: Lorazepam
Drug: Alemtuzumab
Drug: Tacrolimus

First Posted Date: 2009-04-15

Last Posted Date: 2021-08-17

Lead Sponsor: Columbia University

Target Recruit Count: 3

Registration Number: NCT00881556

Locations: 🇺🇸
The Children's Hospital, Aurora, Colorado, United States
🇺🇸
Morgan Stanley Children's Hospital of NYP, New York, New York, United States
🇺🇸
Children's Memorial Hospital, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy